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Stent thrombosis is a rare but devastating event after contemporary stent implantation, [2] [3] [4] [5] [6] typically associated with large myocardial infarction or death. [5] [6] [7] Although current generation drug-eluting stents have demonstrated significantly reduced stent thrombosis compared with first-generation drug-eluting stents, concerns persist in high-risk patient cohorts and with new technologies, such as bioresorbable coronary scaffolds. [8] [9] [10] Likewise, some newer antiplatelet agents have demonstrated reductions in stent thrombosis rates while others (such as vorapaxar in the TRACER trial) have not. Therefore, reliable ascertainment of stent thrombosis remains imperative for device safety and pharmacological efficacy evaluations in clinical trials for an informed benefit risk assessment of novel therapies.
Clinical definitions of stent thrombosis have varied in sensitivity and specificity as a result of the differing levels of evidence required to reach the diagnosis; criteria have ranged from the purely clinical (such as a myocardial infarction involving the target vessel territory) 6, 11 to requiring angiographic confirmation of thrombus. 12, 13 The ARC was a critical initiative that addressed the known variability in adverse event reporting by proposing standardizing end point definitions. ARC stent thrombosis definitions are stratified according to the degree of certainty (possible, probable, or definite), 14 and ARC-defined definite stent thrombosis requires angiographic or autopsy confirmation of thrombosis in addition to clinical correlates (symptoms, ECG findings, or biomarkers). As a result, ARC-definite stent thrombosis is intended to have high specificity at the cost of sensitivity. In contrast, ARC-possible stent thrombosis is the most sensitive but least specific category and includes any unexplained death from 30 days after intracoronary stenting until the end of a trial's follow-up. Beyond stating the requirement for angiographic confirmation of thrombosis, the ARC guidance document is not prescriptive regarding the specific ascertainment methodology for angiographic thrombus confirmation, which arguably could rely on site reports, ACL reports (if available), or visual confirmation by CEC members.
The classic angiographic appearance of thrombus is characterized by any combination of decreased contrast density, haziness, a filling defect, or convex contours with or without contrast staining or reduced flow. A semiquantitative classification of thrombus size has also been proposed. 15 Previous validation studies of thrombus assessment are entirely consistent with the current report and have demonstrated only fair agreement between clinical centers and central core laboratories (κ=0.30), whereas ACL have substantial interobserver agreement for identifying thrombus (κ=0.7). 16 Given the greater reliability and consistency of ACL thrombus assessment compared with clinical centers, ACL assessments (when available) should be an integral part of the source documents provided to the CEC for event adjudication, particularly when the CEC does not review angiograms directly-as was the case in TRACER.
The the ACL rate (1.53% [108/7075]). Therefore, ARC-defined definite stent thrombosis rates reported in studies are not necessarily comparable unless similar evaluation methods and data sources are used. Although the higher stent thrombosis rates reported in registry studies compared with randomized trials are often attributed to higher risk patient populations, the findings of Popma et al indicate that the inherent overestimation of site-reported ST is also a contributor. In contrast, studies reporting only CEC-adjudicated ARC-definite stent thrombosis will have the lowest stent thrombosis rates because of the increased specificity and limitations in obtaining source documents, particularly when ACL analysis or direct review of angiograms do not inform the adjudication process. Furthermore, these findings have consequences for the design and powering of studies. Given that stent thrombosis is rare, the under-reporting by the CEC diminishes the likelihood of detecting significant differences between groups, and the results of the TRACER substudy underscore the critical nature of standardized ascertainment methods in addition to standardized definitions. It is clear from these data that ACL analysis is more sensitive for the detection of stent thrombosis than the CEC, which is to be expected given the CEC dependence on the quality and completeness of source documents. In 50% of the cases in which there was discordance between the ACL and CEC, the CEC did not have sufficient information to adjudicate ARC-definite stent thrombosis. Therefore, additional measures should be taken to improve CEC assessment of stent thrombosis: 
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